Heart health

Heart health after 40 is mostly a question of a few numbers and what each one triggers. This pillar collects the guides that read those numbers the way the guidelines do: the 2025 blood pressure categories and the treatment decisions attached to each, the 2001 cholesterol categories most lab reports still print and the risk-based rule that decides treatment in place of age, the one lipid test worth ordering once in a lifetime, and the trial evidence on walking. Every figure below is restated from the guide it links to, where it carries the primary source and that source's date.

The 2025 AHA/ACC guideline keeps the 2017 categories: normal is below 120 over 80, elevated is 120 to 129 systolic with a diastolic below 80, stage 1 is 130 to 139 or 80 to 89, and stage 2 is 140 or above or 90 or above. What changed is the decision rule. Stage 1 means medication alongside lifestyle change if you have cardiovascular disease, a previous stroke, diabetes or chronic kidney disease, or a 10-year risk of 7.5 percent or more on the PREVENT calculator; without those conditions and below that risk, it means a 3 to 6 month trial of lifestyle change first, then medication if the average stays at or above 130 over 80. The treatment goal for almost every adult is below 130 over 80. Blood pressure ranges explained walks through each category, and the blood pressure reference ledger prints the thresholds with their source rows.

Walking has a measured effect size. A 2021 Cochrane review of 73 randomized trials and 5,060 participants found walking lowered systolic pressure by 4.11 mmHg on moderate-certainty evidence, at a dose the review states plainly: moderate intensity, three to five times a week, 20 to 40 minutes a session, for about three months. Does walking lower blood pressure? reports the diastolic and heart-rate figures and the certainty grades behind each.

The NCEP ATP III cutoffs from 2001 are still the categories most lab reports print: LDL is optimal under 100 mg/dL, near optimal from 100 to 129, borderline high from 130 to 159, high from 160 to 189 and very high at 190 and above; HDL under 40 counts as a major risk factor. No guideline publishes cholesterol targets by decade of age. Age enters once, as an input to your calculated 10-year risk, and the 2018 AHA/ACC guideline's risk-discussion band of LDL 70 to 189 mg/dL applies to adults 40 to 75. Cholesterol levels by age explains why the decade charts elsewhere on the web are not from any guideline.

Two guides cover the numbers a standard panel misses. ApoB vs LDL cholesterol explains why ApoB is a count of atherogenic particles rather than a weight of cholesterol, where the two diverge (high triglycerides, insulin resistance, diabetes), and the 130 mg/dL risk-enhancer threshold in the 2018 guideline. Lipoprotein(a) levels covers the test the European Atherosclerosis Society says to run at least once in adulthood: the level is genetically set, 50 mg/dL is where it is treated as a risk enhancer, and as of August 2026 no drug is approved to lower it. HDL cholesterol explains why raising a low HDL with a drug stopped being a goal after the AIM-HIGH and torcetrapib trials.

Start with your most recent blood pressure and lipid panel. Read the category each number falls in on the biomarker library, then open the guide for the decision that category triggers. If your report has no ApoB or Lp(a) row, the two guides above explain what each would add and who benefits from ordering it once. Nothing here replaces the risk calculation your clinician runs; it is meant to make that conversation shorter and better informed.